Dr. Janice Lu is a clinical professor of medicine in the division of medical oncology at the USC Norris Comprehensive Cancer Center. Dr. Lu is certified by the American Board of Internal Medicine and Medical Oncology. She is also a member of the American Society of Clinical Oncology.
She has extensive experience in clinical trials, breast cancer drug development and has led studies as national protocol chair. She serves as associate director of breast cancer research and director of breast cancer clinical trials at USC Norris Cancer Center.
Dr. Lu completed her Hematology and Medical Oncology fellowship at New York University School of Medicine. She earned her PhD degree in Molecular Biology with Dr. David Allis, a pioneer in the foundations of epigenetics at Rockefeller University. Prior to joining to USC Norris Cancer Center, she served as an Associate Professor of Clinical Medicine in the Division of Hematology and Oncology at UCLA. Dr. Lu also served as the Director of the Breast Medical Oncology Program at SUNY Stony Brook for eight years.
Dr. Lu’s career has focused on the management of women with breast cancer in which she excels with her expertise and warm and caring nature. She is dedicated to the cancer community and serves as a board member for the Cancer Support Community in Santa Monica. Her goal is to utilize her science and medical knowledge to work with each patient on a highly individualized basis with state-of-the-art cancer care.
SUNY at Stony Brook School of Medicine: Maffetone Award for Fighting Breast Cancer, 2010
SUNY at Stony Brook School of Medicine: Carol M. Baldwin Breast Cancer Research Award, 2005
New York University Cancer Center: Translational Research Task Force Award, 2003
Biannual Ovarian Cancer Research Symposium: Hematology/Oncology Fellows Award, 2002
Syracuse University: All-University Doctoral Prize, 1995
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013 Mar 20; 31(9):1157-63. View in: PubMed
Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer. 2010 Feb 1; 126(3):669-83. View in: PubMed
Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer. 2010 Feb 01; 126(3):669-83. View in: PubMed
Novel therapies in breast cancer: what is new from ASCO 2008. J Hematol Oncol. 2008 Oct 01; 1:16. View in: PubMed
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecol Oncol. 2008 Mar; 108(3):500-4. View in: PubMed
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008 Feb; 9(2):117-23. View in: PubMed
Novel therapies in breast cancer: what is new from ASCO 2008. J Hematol Oncol. 2008; 1:16. View in: PubMed
Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy. Hematol Oncol Clin North Am. 2003 Aug; 17(4):969-75. View in: PubMed
Emerging treatments for ovarian cancer. Expert Opin Emerg Drugs. 2003 May; 8(1):203-16. View in: PubMed